» Articles » PMID: 35818510

Cardiovascular Disease in Duchenne Muscular Dystrophy: Overview and Insight Into Novel Therapeutic Targets

Overview
Date 2022 Jul 12
PMID 35818510
Authors
Affiliations
Soon will be listed here.
Abstract

Duchenne muscular dystrophy (DMD) is a devastating disease affecting approximately 1 in every 3,500 male births worldwide. Multiple mutations in the dystrophin gene have been implicated as underlying causes of DMD. However, there remains no cure for patients with DMD, and cardiomyopathy has become the most common cause of death in the affected population. Extensive research is under way investigating molecular mechanisms that highlight potential therapeutic targets for the development of pharmacotherapy for DMD cardiomyopathy. In this paper, the authors perform a literature review reporting on recent ongoing efforts to identify novel therapeutic strategies to reduce, prevent, or reverse progression of cardiac dysfunction in DMD.

Citing Articles

Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy.

Wu R, Li P, Xiao P, Zhang S, Wang X, Liu J Nat Commun. 2025; 16(1):2398.

PMID: 40064877 PMC: 11894210. DOI: 10.1038/s41467-025-57831-5.


Early Cardiac Dysfunction in Duchenne Muscular Dystrophy: A Case Report and Literature Update.

Lupu M, Pintilie I, Teleanu R, Marin G, Vladacenco O, Severin E Int J Mol Sci. 2025; 26(4).

PMID: 40004149 PMC: 11855830. DOI: 10.3390/ijms26041685.


Striking Cardioprotective Effects of an Adiponectin Receptor Agonist in an Aged Mouse Model of Duchenne Muscular Dystrophy.

Abou-Samra M, Dubuisson N, Marino A, Selvais C, Romain V, Davis-Lopez de Carrizosa M Antioxidants (Basel). 2025; 13(12.

PMID: 39765879 PMC: 11674016. DOI: 10.3390/antiox13121551.


Research hotspots and trends for Duchenne muscular dystrophy: a machine learning bibliometric analysis from 2004 to 2023.

Fang P, Han J, An D, Bu Y, Ji G, Liu M Front Immunol. 2024; 15:1429609.

PMID: 39669562 PMC: 11634759. DOI: 10.3389/fimmu.2024.1429609.


Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMD Rats.

Baine S, Wier C, Lemmerman L, Cooper-Olson G, Kempton A, Haile A Hum Gene Ther. 2024; 35(23-24):978-988.

PMID: 39607794 PMC: 11659437. DOI: 10.1089/hum.2024.013.


References
1.
Rafael-Fortney J, Chimanji N, Schill K, Martin C, Murray J, Ganguly R . Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation. 2011; 124(5):582-8. PMC: 3150227. DOI: 10.1161/CIRCULATIONAHA.111.031716. View

2.
Quattrocelli M, Zelikovich A, Jiang Z, Peek C, Demonbreun A, Kuntz N . Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming. JCI Insight. 2019; 4(24). PMC: 6975267. DOI: 10.1172/jci.insight.132402. View

3.
Yasuda S, Townsend D, Michele D, Favre E, Day S, Metzger J . Dystrophic heart failure blocked by membrane sealant poloxamer. Nature. 2005; 436(7053):1025-9. DOI: 10.1038/nature03844. View

4.
Di Virgilio F . Purinergic signalling in the immune system. A brief update. Purinergic Signal. 2008; 3(1-2):1-3. PMC: 2096765. DOI: 10.1007/s11302-006-9048-5. View

5.
Good M, Chiu Y, Poon I, Medina C, Butcher J, Mendu S . Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug Spironolactone. Circ Res. 2017; 122(4):606-615. PMC: 5815904. DOI: 10.1161/CIRCRESAHA.117.312380. View